News headlines about Illumina (NASDAQ:ILMN) have trended somewhat positive on Wednesday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Illumina earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the life sciences company an impact score of 45.106907098522 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern’s scoring:
Illumina (ILMN) traded up $0.63 during trading hours on Wednesday, reaching $242.05. 738,313 shares of the company were exchanged, compared to its average volume of 901,641. Illumina has a 1 year low of $156.50 and a 1 year high of $248.97. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The stock has a market cap of $35,340.00, a price-to-earnings ratio of 45.67, a price-to-earnings-growth ratio of 3.30 and a beta of 0.79.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period last year, the firm posted $0.97 EPS. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis. equities research analysts anticipate that Illumina will post 3.76 earnings per share for the current year.
A number of brokerages have recently issued reports on ILMN. Deutsche Bank set a $275.00 target price on shares of Illumina and gave the stock a “buy” rating in a research report on Tuesday. BTIG Research restated a “hold” rating on shares of Illumina in a research report on Tuesday. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. William Blair lowered shares of Illumina from an “outperform” rating to a “market perform” rating in a research report on Friday, January 5th. Finally, Evercore ISI began coverage on shares of Illumina in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $250.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $220.13.
In other Illumina news, EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $206.88, for a total transaction of $413,760.00. Following the sale, the executive vice president now directly owns 34,579 shares in the company, valued at approximately $7,153,703.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the sale, the director now owns 539,176 shares in the company, valued at $113,458,805.68. The disclosure for this sale can be found here. Insiders have sold a total of 137,671 shares of company stock worth $29,485,768 over the last 90 days. Insiders own 0.89% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Illumina (ILMN) Share Price” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/17/illumina-ilmn-earning-somewhat-positive-media-coverage-report-finds.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.